The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
US sweet protein startup Oobli has raised $18M and partnered with global ingredients giant Ingredion to develop ...
Novo Nordisk (NYSE: NVO) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...
Weight loss drugs continue to make headlines.  A new study conducted by researchers from the University of Southern ...
A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
Ozempic and similar drugs are popular with consumers for their weight-loss properties, but a new study suggests they could ...
Doctors have begun noticing a trend: they all seem to get full before finishing dinner, and it's likely thanks to drugs like ...